Sun, Sep 21, 2014, 3:44 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Cellceutix Corporation Message Board

  • jbcoopertire jbcoopertire Dec 28, 2012 12:54 PM Flag


    I have been very fortunate in investing in biopharm stocks. What I have found though is investors that are easily lead by bad information both pro and con. I am blessed by the fact that before becoming an investor I had worked in an academic setting that required a great deal of research. Research became second nature. I would delve into any area that was important to me. I am amazed at what passes for due diligence in this area. I have been burned twice by articles written by Adam Frueurstein. This man has no scientific credentials yet his word sends stock up and down. Last evening I read the SA article by Ben S. I researched the writer. He is an investor. Now that might make him a good analyst. I don't know. There is not enough information to make a judgement. However I do have certain information about CTIX. One I know that there initial research was strong enough to convince the board at Dana Farber to partner with them on research for Kevetrin. Now I have a motive for owning stock. Self enrichment. Dana Farber has a motive too: To keep Harvard on the cutting edge of medical research and achievement. While we have yet to see the results of these tests we do know that it has done well enough to start the second cohort with no changes. What we can ascertain with our own eyes is enough to tell me that CTIX is the real thing. MDAnderson has started talks with them about becoming part of their test. Again believe that Anderson has done their own DD before inviting CTIX to become part of their protocol.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Dana Farber is not paying for clinical Phase I trials as has been stated incorrectly on this board. Rather, the agreement with Aspire(read the SECs) will do that as this is a cash poor company and will likely be diluted more in the future. Beth Israel Deaconess Medical Center, did agree to test Kevetrin with multi kinase inhibitors (owned by Pfizer) for melanoma and renal cell carcinoma (likely Sutent/Nexavar, etc). This is completely independent of the Phase I trials and will be paid for by government grants/funding, and this is likely the same with the announcement yesterday with 'famous southwestern hospital' or whatever. Additionally, the likely reason Phase I trials are being conducted at DF are because of the previous relationship/employment of Dr. Menon. The fact that DF is allowing Cellceutix to conduct Phase I studies there does not mean anything other than that, they are not financing the studies. DF does extensive Phase I cancer drug studies most of which fail.

      Dr. Menon started on the path to Kevetrin when doing a post mortem on a bull who had been sprayed for ticks with a chemical substance. When the bull died, Dr. Menon found the substance also reduced subcutaneous tumors existing on the bull. While I really, really hope that Kevetrin succeeds, it is true that all the research published by Cellcuetix is in house and has not peer reviewed. The published research given by the company does sound extremely positive. Also, it should also be noted that there seems to be some "pumping" of Dr. Menon's credentials regarding previous patents with Lilly for Altima, etc, the same skepticism applies for company PRs...

      This company has atrocious financials. If Kevetrin is successful in humans(fingers crossed) this could be a huge cancer breakthrough. This company could be bought by big pharma but will never make it on their own IMO. Only time will answer those questions. Anything negative, Kevetrin is worth $0 and this company rides on Prurisol.

      I would only invest what I was willing to lose, could be a winner or a big loser, but not enough information yet to know, IMO.

    • How do you know MD Anderson began talks with them?

2.29-0.08(-3.38%)Sep 19 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.